Table 2.
Demographics of the PD-1 inhibitor cohort
| Overall | No tumor shrinkage | 1%–25% | 26%–50% | 51%–75% | 76%–100% | |
|---|---|---|---|---|---|---|
| (n = 355) | (n = 168) | (n = 70) | (n = 44) | (n = 45) | (n = 28) | |
| Age | ||||||
| Median | 61 | 63 | 61 | 62 | 60 | 64 |
| Range | 39, 85 | 39, 81 | 40, 85 | 46, 76 | 42, 84 | 48, 81 |
| Gender | ||||||
| Male | 221 (62%) | 101 (60%) | 45 (64%) | 28 (64%) | 33 (73%) | 14 (50%) |
| Female | 134 (38%) | 67 (40%) | 25 (36%) | 16 (36%) | 12 (27%) | 14 (50%) |
| Race | ||||||
| White | 321 (90%) | 156 (93%) | 62 (89%) | 39 (89%) | 39 (87%) | 25 (89%) |
| Black or AA | 10 (3%) | 4 (2%) | 1 (1%) | 1 (2%) | 4 (9%) | 0 |
| Asian | 13 (4%) | 4 (2%) | 3 (4%) | 3 (7%) | 1 (2%) | 2 (7%) |
| Other | 11 (3%) | 4 (2%) | 4 (6%) | 1 (2%) | 1 (2%) | 1 (4%) |
| Region | ||||||
| USA | 120 (34%) | 55 (33%) | 20 (29%) | 12 (27%) | 19 (42%) | 14 (50%) |
| Non-USA | 235 (66%) | 113 (67%) | 50 (71%) | 34 (73%) | 26 (58%) | 14 (50%) |
| ECOG PS | ||||||
| 0 | 103 (29%) | 41 (24%) | 21 (30%) | 15 (24%) | 15 (33%) | 11 (39%) |
| 1 | 252 (71%) | 127 (76%) | 49 (70%) | 29 (66%) | 30 (67%) | 17 (61%) |
| Smoking status | ||||||
| Current/former | 295 (83%) | 132 (79%) | 59 (84%) | 40 (91%) | 39 (87%) | 25 (89%) |
| Never | 57 (16%) | 34 (20%) | 11 (16%) | 4 (9%) | 5 (11%) | 3 (11%) |
| Missing | 3 (<1%) | 2 (1%) | 0 | 0 | 1 (2%) | 0 |
| Histology | ||||||
| Sq | 120 (34%) | 56 (33%) | 22 (31%) | 18 (41%) | 18 (40%) | 6 (21%) |
| NSq | 235 (66%) | 112 (67%) | 48 (69%) | 26 (59%) | 27 (60%) | 22 (79%) |